Literature DB >> 14507670

A human-mouse chimera of the alpha3alpha4alpha5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- Alport mice.

Laurence Heidet1, Dorin-Bogdan Borza, Mélanie Jouin, Mireille Sich, Marie-Geneviève Mattei, Yoshikazu Sado, Billy G Hudson, Nicholas Hastie, Corinne Antignac, Marie-Claire Gubler.   

Abstract

Collagen IV is a major structural component of basement membranes. In the glomerular basement membrane (GBM) of the kidney, the alpha3, alpha4, and alpha5(IV) collagen chains form a distinct network that is essential for the long-term stability of the glomerular filtration barrier, and is absent in most patients affected with Alport syndrome, a progressive inherited nephropathy associated with mutation in COL4A3, COL4A4, or COL4A5 genes. To investigate, in vivo, the regulation of the expression, assembly, and function of the alpha3alpha4alpha5(IV) protomer, we have generated a yeast artificial chromosome transgenic line of mice carrying the human COL4A3-COL4A4 locus. Transgenic mice expressed the human alpha3 and alpha4(IV) chains in a tissue-specific manner. In the kidney, when expressed onto a Col4a3(-/-) background, the human alpha3(IV) chain restored the expression of and co-assembled with the mouse alpha4 and alpha5(IV) chains specifically at sites where the human alpha3(IV) was expressed, demonstrating that the expression of all three chains is required for network assembly. The co-assembly of the human and mouse chains into a hybrid network in the GBM restores a functional GBM and rescues the Alport phenotype, providing further evidence that defective assembly of the alpha3-alpha4-alpha5(IV) protomer, caused by mutations in any of the three chains, is the pathogenic mechanism responsible for the disease. This line of mice, humanized for the alpha3(IV) collagen chain, will also provide a valuable model for studying the pathogenesis of Goodpasture syndrome, an autoimmune disease caused by antibodies against this chain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14507670      PMCID: PMC1868284          DOI: 10.1016/s0002-9440(10)63520-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

1.  Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains.

Authors:  A Boutaud; D B Borza; O Bondar; S Gunwar; K O Netzer; N Singh; Y Ninomiya; Y Sado; M E Noelken; B G Hudson
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

2.  Differential expression of mouse alpha5(IV) and alpha6(IV) collagen genes in epithelial basement membranes.

Authors:  K Saito; I Naito; T Seki; T Oohashi; E Kimura; R Momota; Y Kishiro; Y Sado; H Yoshioka; Y Ninomiya
Journal:  J Biochem       Date:  2000-09       Impact factor: 3.387

3.  Novel COL4A5/COL4A6 deletions and further characterization of the diffuse leiomyomatosis-Alport syndrome (DL-AS) locus define the DL critical region.

Authors:  L Heidet; L Cohen-Solal; E Boye; P Thorner; M J Kemper; A David; L Larget Piet; J Zhou; F Flinter; X Zhang; M C Gubler; C Antignac
Journal:  Cytogenet Cell Genet       Date:  1997

4.  Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome.

Authors:  S Gunwar; F Ballester; M E Noelken; Y Sado; Y Ninomiya; B G Hudson
Journal:  J Biol Chem       Date:  1998-04-10       Impact factor: 5.157

5.  Epitope-defined monoclonal antibodies against type-IV collagen for diagnosis of Alport's syndrome.

Authors:  M Kagawa; Y Kishiro; I Naito; T Nemoto; H Nakanishi; Y Ninomiya; Y Sado
Journal:  Nephrol Dial Transplant       Date:  1997-06       Impact factor: 5.992

6.  Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys.

Authors:  L Heidet; Y Cai; L Guicharnaud; C Antignac; M C Gubler
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

7.  Role for transforming growth factor-beta1 in alport renal disease progression.

Authors:  R Sayers; R Kalluri; K D Rodgers; C F Shield; D T Meehan; D Cosgrove
Journal:  Kidney Int       Date:  1999-11       Impact factor: 10.612

8.  Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome.

Authors:  Laurence Heidet; Christelle Arrondel; Lionel Forestier; Lola Cohen-Solal; Geraldine Mollet; Bruno Gutierrez; Christophoros Stavrou; Marie Claire Gubler; Corinne Antignac
Journal:  J Am Soc Nephrol       Date:  2001-01       Impact factor: 10.121

9.  Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy.

Authors:  D Cosgrove; K Rodgers; D Meehan; C Miller; K Bovard; A Gilroy; H Gardner; V Kotelianski; P Gotwals; A Amatucci; R Kalluri
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

10.  Differential expression of type IV collagen isoforms, alpha5(IV) and alpha6(IV) chains, in basement membranes surrounding smooth muscle cells.

Authors:  T Seki; I Naito; T Oohashi; Y Sado; Y Ninomiya
Journal:  Histochem Cell Biol       Date:  1998-10       Impact factor: 4.304

View more
  26 in total

1.  Murine membranous nephropathy: immunization with α3(IV) collagen fragment induces subepithelial immune complexes and FcγR-independent nephrotic syndrome.

Authors:  Jun-Jun Zhang; Mahdi Malekpour; Wentian Luo; Linna Ge; Florina Olaru; Xu-Ping Wang; Maimouna Bah; Yoshikazu Sado; Laurence Heidet; Sandra Kleinau; Agnes B Fogo; Dorin-Bogdan Borza
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

2.  Identification of the NC1 domain of {alpha}3 chain as critical for {alpha}3{alpha}4{alpha}5 type IV collagen network assembly.

Authors:  Valerie LeBleu; Malin Sund; Hikaru Sugimoto; Gabriel Birrane; Keizo Kanasaki; Elizabeth Finan; Caroline A Miller; Vincent H Gattone; Heather McLaughlin; Charles F Shield; Raghu Kalluri
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

3.  Cellular origins of type IV collagen networks in developing glomeruli.

Authors:  Dale R Abrahamson; Billy G Hudson; Larysa Stroganova; Dorin-Bogdan Borza; Patricia L St John
Journal:  J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 10.121

4.  Identification of noncollagenous sites encoding specific interactions and quaternary assembly of alpha 3 alpha 4 alpha 5(IV) collagen: implications for Alport gene therapy.

Authors:  Jeong Suk Kang; Selene Colon; Thomas Hellmark; Yoshikazu Sado; Billy G Hudson; Dorin-Bogdan Borza
Journal:  J Biol Chem       Date:  2008-10-16       Impact factor: 5.157

5.  Quaternary epitopes of α345(IV) collagen initiate Alport post-transplant anti-GBM nephritis.

Authors:  Florina Olaru; Wentian Luo; Xu-Ping Wang; Linna Ge; Jens Michael Hertz; Clifford E Kashtan; Yoshikazu Sado; Yoav Segal; Billy G Hudson; Dorin-Bogdan Borza
Journal:  J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 10.121

Review 6.  Complexities of the glomerular basement membrane.

Authors:  Richard W Naylor; Mychel R P T Morais; Rachel Lennon
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

7.  Diagnosis of Alport syndrome without biopsy?

Authors:  Marie Claire Gubler
Journal:  Pediatr Nephrol       Date:  2006-12-02       Impact factor: 3.714

Review 8.  Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome.

Authors:  Dominic Cosgrove; Shiguang Liu
Journal:  Matrix Biol       Date:  2016-08-27       Impact factor: 11.583

9.  Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane.

Authors:  Rosa M Baleato; Petrina L Guthrie; Marie-Claire Gubler; Leonie K Ashman; Séverine Roselli
Journal:  Am J Pathol       Date:  2008-09-11       Impact factor: 4.307

10.  Human podocytes adhere to the KRGDS motif of the alpha3alpha4alpha5 collagen IV network.

Authors:  Corina M Borza; Dorin-Bogdan Borza; Vadim Pedchenko; Moin A Saleem; Peter W Mathieson; Yoshikazu Sado; Heather M Hudson; Ambra Pozzi; Juan Saus; Dale R Abrahamson; Roy Zent; Billy G Hudson
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.